Li Lei, Lu Yingyuan, Du Zhiyong, Fang Meng, Wei Ying, Zhang Wenxin, Xu Yisheng, Sun Jiaxu, Zeng Xiangrui, Hu Guomin, Wang Lingli, Jiang Yong, Liu Shuwang, Tang Yida, Yu Haiyi, Tu Pengfei, Guo Xiaoyu
Department of Cardiology, Peking University Third Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University; Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100191, China.
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
J Transl Int Med. 2024 Nov 6;12(5):495-509. doi: 10.1515/jtim-2023-0141. eCollection 2024 Nov.
Atrial fibrillation (AF) and coronary heart disease (CHD) are closely related to metabolic dysregulation. However, the metabolic characteristics of AF patients with concomitant CHD remain unclear. The aims of this study were to elucidate the metabolic profiles of patients with AF and CHD to seek new therapeutic targets and related factors of AF combined with CHD.
Untargeted metabolomics and targeted oxylipins profiling were performed to characterize the serum metabolome landscape of patients with AF, CHD, and AF comorbid CHD.
The serum metabolic fingerprints of patients with AF comorbid CHD were significantly differentiated from normal controls (NC) and individuals with AF or CHD alone, and the differentiated metabolites dominated by a variety of lipid alterations in the phospholipid and fatty acid metabolism. Furthermore, the targeted profiles of oxylipins demonstrated that the levels of arachidonic acid derivatives including prostaglandins, leukotrienes, hydroxy-docosahexaenoic acids, hydroxy-eicostetraenoic acids and hydroxy-eicosatrienoic acids in patients with AF and CHD were significantly different from those in the NC, AF, and CHD groups. Several prostaglandins were positively associated with echocardiographic indicators of myocardial remodeling.
This study updates metabolic insights of AF and CHD and provides potential therapeutic targets for preventing or treating AF comorbid CHD.
心房颤动（AF）和冠心病（CHD）均与代谢失调密切相关。然而，合并冠心病的房颤患者的代谢特征仍不明确。本研究旨在阐明房颤合并冠心病患者的代谢谱，以寻找新的治疗靶点以及与房颤合并冠心病相关的因素。
采用非靶向代谢组学和靶向氧化脂质分析来表征房颤、冠心病及房颤合并冠心病患者的血清代谢组特征。
房颤合并冠心病患者的血清代谢指纹与正常对照组（NC）以及单独患有房颤或冠心病的个体有显著差异，且差异代谢物主要由磷脂和脂肪酸代谢中的多种脂质变化主导。此外，氧化脂质的靶向分析表明，房颤合并冠心病患者中花生四烯酸衍生物（包括前列腺素、白三烯、羟基二十二碳六烯酸、羟基二十碳四烯酸和羟基二十碳三烯酸）的水平与NC、房颤和冠心病组有显著差异。几种前列腺素与心肌重塑的超声心动图指标呈正相关。
本研究更新了对房颤和冠心病的代谢认识，并为预防或治疗房颤合并冠心病提供了潜在的治疗靶点。
